ANVS 424B5 SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

ANVS ▼ -1.47% at T+5d

SHORT call ✓ call won +1.47% · α vs SPY +2.71% · entry $2.04 → $2.01

Next anchor: T+20d in 7d

Last close $1.79 (close Jun 8) · +12.25% from $2.04 entry (call sign-flipped)

Entry anchored
May 19, 05:02 PM ET
via Databento tick

T+1d

+5.39%

call -5.39% · α -5.20%

$2.15

settled 21d ago

T+5d

-1.47%

call +1.47% · α +2.71%

$2.01

settled 14d ago

T+20d

—

call — · α —

—

in 7d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Annovis Bio filed a preliminary 424B5 for an underwritten offering of common stock and warrants, with no final pricing disclosed. The company has a going concern, cash of $14.2M (insufficient for 12 months), and an accumulated deficit of $181.3M. The offering will be highly dilutive to existing shareholders.

Actionable Insight

Expect further downward pressure on ANVS as the market prices in substantial dilution. Monitor for final pricing and size—larger offerings amplify the negative impact. The company's cash runway extension is the only offsetting factor, but near-term stock performance will likely be weak.

Key Facts

Preliminary prospectus for offering of common stock and warrants (nine-tenths warrant per share, six-year term).
Cash and cash equivalents of $14.2M as of March 31, 2026, insufficient to fund operations for the next 12 months.
Accumulated deficit of $181.3M; going concern uncertainty noted.
Phase 3 Alzheimer's trial enrollment 85% complete; cash expected to last only until Q4 2026.
Prior registered direct offering in April 2026 raised $9.3M net at $1.90/unit.
This filing follows Q1 2026 earnings (May 15, 2026) that showed increased net loss and cash burn.

Financial Impact

Unknown offering size; no pricing disclosed. However, dilution will be significant given the company's $71M market cap and urgent need for capital.

dilutionshare countcash position

Risk Factors

Dilution from the offering may significantly reduce per-share value.
If the offering is larger than expected, selling pressure could be severe.
Failure to complete the offering would force a drastic reduction in operations or a distressed financing.
Phase 3 Alzheimer's trial results remain binary and could wipe out remaining value if negative.

Market Snapshot

Exchange

NYSE

Sector

Pharmaceutical Preparations

Analyst Consensus

90% bullish (10 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

Document	Accession Number
424B5 Filing (Primary)	0001104659-26-063959
Document: 0001104659-26-063959-index-headers.html	0001104659-26-063959
Document: 0001104659-26-063959-index.html	0001104659-26-063959
Document: 0001104659-26-063959.txt	0001104659-26-063959

7 reports for ANVS

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for ANVS — sortable, filterable
	Type				Now
May 20, 2026 20d ago	424B5 BEARISH ★ 6/10	$2.15 $1.90	▲ +11.63%	▲ +13.23%	$1.79 (+16.74%)
May 19, 2026 21d ago	424B5 BEARISH ★ 7/10	$2.04 $2.01	▲ +1.47%	▲ +2.71%	$1.79 (+12.25%)
May 15, 2026 25d ago	8-K MIXED ★ 5/10	$2.05 $2.06	▲ +0.49%	▼ −1.13%	$1.79 (−12.68%)
May 15, 2026 25d ago	Press Release BEARISH ★ 6/10	$2.06 $2.23	▼ −8.25%	▼ −7.29%	$1.79 (+13.11%)
Apr 10, 2026 8w ago	Press Release MIXED ★ 6/10	$1.59 $1.87	▲ +17.61%	▲ +13.11%	$1.79 (+12.58%)
Mar 19, 2026 11w ago	Press Release NEUTRAL ★ 4/10	$2.67 $2.15	▼ −19.48%	▼ −17.26%	$1.79 (−32.96%)
Mar 16, 2026 12w ago	Press Release MIXED ★ 6/10	$2.83 $2.50	▼ −11.66%	▼ −9.62%	$1.79 (−36.75%)

US Market Status

Market Closed — Opens in 7h 19m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access